Sanofi · 1 week ago
Head of US Gross to Net Finance
Morristown, NJ
Full-time
Onsite
Director/Executive
10+ years expSanofi is an R&D-driven, AI-powered biopharma company committed to improving people’s lives. The US Head of Gross-to-Net is a strategic leadership role responsible for the integrity and strategic direction of GTN forecasting, reporting, and reserve governance, ensuring financial stewardship over gross-to-net outcomes.
Health CareLife SciencePharmaceuticalTherapeutics
Responsibilities
Provide financial stewardship over $45B+ in gross sales, ensuring alignment between accounting, forecasting, performance analytics, and cash flow implications
Lead and develop a high-performing organization of ~15 team members with ~6 direct reports, including clear decision rights, escalation paths, and succession planning
Lead GTN reserve governance: Own quarterly GTN reserve analysis and adequacy reviews, ensuring reserves are accurate, risks/opportunities are identified early, and key assumptions and rates are well captured
Own GTN forecasting cadence: Lead GTN forecasting and actuals processes in partnership with GBUs, Finance Business Partners, Market Access; drive alignment, transparency, and forecast accuracy
Deliver decision-shaping insights: Provide financial insights on GTN programs, payer/channel mix, product launches, and contract structures to support leadership decisions
Evaluate pricing and access impacts: Assess the financial impact of pricing strategies, market access programs, and payer negotiations; translate assumptions into clear implications for profitability and performance
Lead cross-functional alignment: Lead cross-functional sessions to align assumptions, resolve variances, and improve forecast accuracy
Ensure close, controls, and audit readiness: Oversee governance of net sales close activities and supporting GTN processes; serve as the senior point of contact for internal/external audits and ensure strong evidence and remediation discipline
Lead and develop the CoE: Drive process improvements, automation, and AI-enabled forecasting and scenario modeling (e.g., early-warning indicators and anomaly detection) to increase speed, transparency, and consistency across forecasting, reserves, and close
Qualification
Required
Minimum 10+ years relevant Accounting/Finance/Industry experience
B.A/B.S. Accounting/Finance, or related field
Pharma/biotech experience required
Experience leading GTN/revenue forecasting and reserves governance in a complex organization
Ability to influence, drive and manage innovation
Exhibits political and interpersonal savvy
Sees the 'big picture' and reads emerging trends and patterns very effectively
Demonstrates strategic agility
Able to effectively manage competing priorities with consideration to the highest level of business impact and maintain control over multiple priorities simultaneously
Builds strong and effective teams, encourages others to develop new or higher levels of skills and knowledge
Possesses a strong sense of urgency
Generally remains calm and collected regardless of pressure
Consistently demonstrates an entrepreneurial spirit and fosters a culture of innovation
Challenges the status quo and applies a thoughtful risk taking approach
Preferred
CPA and/or MBA preferred
Benefits
High-quality healthcare
Prevention and wellness programs
At least 14 weeks’ gender-neutral parental leave
Company
Sanofi
Sanofi is a global biopharma company focused on prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases.
10001+ employees
H1B Sponsorship
Sanofi has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (101)
2024 (68)
2023 (59)
2022 (78)
2021 (38)
2020 (38)
Funding
Current Stage
Public CompanyTotal Funding
$6.97BKey Investors
Blackstone Life SciencesEvotec
2025-10-28Post Ipo Debt· $3B
2025-06-17Post Ipo Debt· $1.74B
2025-03-05Post Ipo Debt· $1.59B
Leadership Team
Paul Hudson
Chief Executive Officer
Francois-Xavier Roger
Chief Financial Officer
Recent News
2026-01-25
BioWorld Financial Watch
2026-01-25
2026-01-24
Company data provided by crunchbase